ATS Breathe Easy - How Bronchiectasis is Entering a New Era of Targeted Therapy copertina

ATS Breathe Easy - How Bronchiectasis is Entering a New Era of Targeted Therapy

ATS Breathe Easy - How Bronchiectasis is Entering a New Era of Targeted Therapy

Ascolta gratuitamente

Vedi i dettagli del titolo

Offerte di stagione | 0,99 €/mese per i primi 3 mesi

A seguire 9,99 €/mese – si applicano condizioni. Puoi disdire mensilmente.

With the FDA approval of brensocatib, the first approved treatment specifically for non-cystic fibrosis bronchiectasis, what does this breakthrough mean for patients and clinicians? In this episode of the ATS Breathe Easy podcast, host Ugo Ezema, MD, Tulane, speaks with ATS Treasurer Gregory Tino, MD, ATSF, University of Pennsylvania, about the science behind brensocatib, findings from the ASPEN clinical trial, and promising new therapies on the horizon.

adbl_web_anon_alc_button_suppression_t1
Ancora nessuna recensione